Company news
Intellia Therapeutics, Inc. news in 2026
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
November 12, 2026
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
November 10, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 6, 2026
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
November 5, 2026
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
November 4, 2026
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
November 3, 2026
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
October 29, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 28, 2026
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
October 13, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
September 8, 2026
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
September 4, 2026
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
September 4, 2026
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
July 30, 2026
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
June 13, 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
June 1, 2026
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 11, 2026
Intellia Announces Proposed Public Offering of Common Stock
April 27, 2026
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
April 27, 2026
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
April 27, 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
April 24, 2026
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 3, 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
March 2, 2026
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
February 26, 2026
Intellia Therapeutics to Participate in Upcoming Investor Conferences
February 23, 2026
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
February 20, 2026
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
February 19, 2026
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
January 26, 2026
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 1, 2026
Calls in 2026
Decks in 2026
- Investor Day (November 2026)
Investor day · 74 slides · Nov 12, 2026
- Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
- Technical Presentation (April 2026)
Technical · 32 slides · Apr 27, 2026
- Investor Presentation (January 2026)
Investor deck · 37 slides · Jan 9, 2026